1. Introduction
Alkaptonuria is a rare autosomal recessive metabolic disease characterized by excretion of an abnormal amount of homogentisic acid (HGA), a metabolite of phenylalanine and tyrosine, due to the deficiency of homogentisate 1, 2-dioxygenase, which readily converts HGA to maleylacetoacetic acid.1 The lack of dioxygenase enzyme leads to a dramatic elevation in HGA levels in the blood and urine (Fig. 1).1 In Slovakia and the Dominican Republic, the incidence of alkaptonuria has been reported to be as high as 1 in 19,000; however, the worldwide incidence is much lower at 1 in 250,000.2, 3
Fig. 1.Enzyme defect in alkaptonuria.
The three major manifestations of alkaptonuria include dark urine, arthritis in the large weight-bearing joints, and black onchronosis (bluish-black pigmentation in the connective tissue) of the cartilage and collagenous tissue.4 Discoloration of urine-filled diapers is the earliest clinical symptom. The complications of this disease include stone formation in kidneys, gall bladder, prostate, and salivary glands; rupture of tendons, muscles, and ligaments; and cardiovascular manifestations such as aortic valve disease and cardiac arrhythmia.5
For quantitative and semi-quantitative analysis of HGA, the currently available technologies include enzymatic spectrophotometry,6 high-performance liquid chromatography (HPLC),7 mid-infrared spectrometry,8 liquid chromatography with mass spectrometry (LC-MS/MS),9 and gas chromatography mass spectrometry (GC-MS).10 Trimethylsilyl derivatives are the most commonly employed silylation derivatization procedures for GC-MS analysis.11 Until now, reports on derivatization techniques with HGA have included trimethylsilyl (TMS)10 and tert-butyldimethylsilyl (TBDMS) derivatives.12 Most reports require a relatively large volume of derivatizing reagent10 and a long reaction time.12 The present study demonstrated a more effective quantitative analysis method for plasma HGA using GC-MS combined with fast and simple LLE.
2. Experimental Method
2.1. Materials
Homogentisic acid ((2, 5-dihydroxyphenyl) acetic acid) was purchased from TCI Co. (Tokyo, Japan). All other chemicals and organic solvents including acetonitrile and methanol were analytical reagent grade and purchased from J. T. Baker or Yakuri Pure Chemical Co., Ltd. (Osaka, Japan). Tropic acid was used as an internal standard and was purchased from Sigma-Aldrich. REGISIL®, a combination of BSTFA (N, O-bis (trimethylsilyl) trifluoroacetamide) and 10% TMCS (trimethylchlorosilane), was used as a derivatization reagent and was purchased from Sigma-Aldrich (MA, USA). Triethylamine (TEA) was purchased from Sigma-Aldrich. Distilled water was prepared using a Millipore-Milli QTM. Thermo vap (TAITEC model DTU-2C) (Tokyo, Japan) was used for evaporation and derivatization. A shaker (TAITEC, Tokyo, Japan) and a centrifuge (Eppendorf model 5424) (Hamburg Germany) were used for mixing and centrifuging the specimens in different steps.
2.2. Specimen collection and preparation of standard solution
Plasma specimens for analysis were collected in polyethylene bottles from three healthy volunteers (18-30 years of age). The plasma specimens were immediately stored at −20℃ until the analyses. All control subjects were subjected to the same diagnostic procedure at the same facility.
Stock solutions of homogentisic acid and tropic acid were dissolved in methanol (1,000 µg/mL) and stored in a refrigerator until analysis. Each stock solution was further diluted to 1-100 ng/µL with methanol as working solution.
2.3. Instrument and analytical conditions
We used a Hewlett-Packard-6890 Series II GC-MS system (PA, USA) consisting of a Model 6890N gas chromatograph, a Model 5973N mass-selective detector (a HP Hewlett-Packard 3365 MSD Chemstation), and a Model 7683 series injector. An HP-5 Column (30 m × 0.25 mm I.D., 0.25 µm) was purchased from Agilent Technologies. Helium as a carrier gas was set to a flow rate of 0.8 mL/min. The GC oven temperature was programmed from 80 ℃ (2 min hold) to 120 ℃ at a rate of 30 ℃/min, to 160 ℃ at a rate of 20 ℃/min, and finally to 300 ℃ (3 min hold) at a rate of 30 ℃/min, with a total run time of 8.5 min. The temperatures of the inlet and the interface were 280 ℃ and 300 ℃, respectively. The MS was executed in selected ion monitoring (SIM) mode with a dwell time of 100 ms. The molecular ion ([M]+) was selected as the conformation ion (CI), and the ion with highest abundance was chosen as the quantification ion (QI).
One-µL aliquots of the final derivative were injected into the GC-MS ion source at a split ratio of 10:1.
2.4. Sample preparation and derivatization
A 200 µL plasma specimen was combined with 600 µL of methanol in an eppendorf tube. The mixture was centrifuged at 5,000 rpm at room temperature for 3 min. The precipitate was discarded, and the supernatant was transferred to a glass tube. Then, 50 µL of tropic acid (100 ng/µL) was added to 100 µL of the plasma sample in a glass tube as the internal standard. Sodium chloride was added until saturation. Two mL of ethyl acetate was vortex mixed for 10s and centrifuged at 2,000 rpm for 3 min, and then the upper layer was transferred to another glass test. Moisture free extract (sodium sulfate) was evaporated to dryness at 80 ℃ under a gentle stream of nitrogen.
The TMS derivative of carboxylic and hydroxyl functional groups was derived by adding 50 µL of REGISIL and 50 µL of 1% trimethylamine in acetonitrile. After a gentle vortex mixing for 1 min, the mixture was then reacted at 80 ℃ for 5 min. The completed TMS derivatives were cooled for 5 min and transferred to a vial containing a low-volume insert (200 µL) for analysis with GC-MS.
2.5. Calibration
The calibration was performed by spiking pooled plasma specimen with 1, 3, 10, 30, and 100 ng/µL of HGA. An internal standard (50 µL of tropic acid (100 ng/µL)) was also added to the pooled plasma specimens.
2.6. Validation
Our method was validated according to the US Food and Drug Administration (FDA) bioanalytical method validation guidelines.13
The analyte concentration at which the signal-to-noise ratio was greater than 3 was chosen as the limit of detection (LOD), and that greater than 10 was chosen for limit of quantitation (LOQ).13 We evaluated the matrix effect for HGA, which was determined by calculating the ratio of the peak area in the presence of matrix to the peak area in the absence of matrix at low, medium, and high concentrations.13
The carryover effect was evaluated through the injection of the high concentration calibrator followed by a blank injection. Accuracy for intra-day and inter-day assay was measured by the following equation; [measured concentration–apparent concentration]/[apparent concentration] × 100%.14 Precision for intra-day and inter-day assay was calculated using standard spiked pooled plasma and was expressed as coefficient of variation (CV). Recovery tests were performed by comparing quantitative result of extracted and non-extracted spiked plasmas after fortified with low (2 ng/µL), medium (20 ng/µL), and high (80 ng/µL) concentration of HGA, respectively.
3. Results
The linear dynamic range of HGA standard solution was in the range of 1.0 to 100 ng/µL.
TMS derivatization reactions of the 1 carboxylic and 2 hydroxyl functional groups of HGA were quantitatively completed by adding BSTFA including 10% TMCS with 1% TEA in acetonitrile (Fig. 2).
Fig. 2.Reaction scheme of TMS derivative for homogentisic acid.
The chromatogram of the HGA-3TMS derivatives was well resolved from plasma matrix (Fig. 3A).
Fig. 3.GC-MS profile of homogentisic acid-TMS derivatives. (A) HGA standard, (B) normal plasma (male), (C) normal plasma (female).
The mass spectrum was obtained at electron impact ionization mode in full scan with a scan range from 50 to 550 m/z. Molecular ion (m/e 384), and other fragmentation ion of HGA, and trimethylsilyl ion ([Si(CH3)3], 73 m/z) were confirmed concurrent with library matching (Fig. 4).
Fig. 4.Mass spectrum of TMS derivative for homogentisic acid.
To optimize the response of derivatizing reagents for HGA, different TMS reagents (BSTFA, MSTFA and REGISIL®) were compared with its respective responses (Fig. 5). Among these three reagents, REGISIL showed the highest response for HGA and internal standard. Optimum reaction temperature for HGA was compared and then 80 ℃ was chosen as generally known (data not shown). Optimum derivatization reaction time was chosen as 5 min with REGISIL at 80 ℃, showed highest peak intensity (Fig. 6).
Fig. 5.Optimization of derivatization reagent for homogentisic acid.
Fig. 6.Optimization of derivatization reaction time for homogentisic acid.
Linear range of calibration curve on HGA spiked on plasma ranged from 1.0-100.0 ng/µL with a correlation coefficient of 0.9991 (y=1.4863x−0.0072), showing excellent linearity (Fig. 7) by linear regression analysis. Limit of detection and limit of quantification were determined as 0.4 ng/µL and 4 ng/µL, respectively for developed method. To observe a carry-over effect, six blank plasmas were run after running the highest concentration of HGA and demonstrated no visible interference peak (data not shown).
Fig. 7.Calibration curve of homogentisic acid for GC/MS-SIM analysis (n=3).
Precision and accuracy of the method were evaluated on standard spiked plasma at 3 different concentration for intra-day and inter-day assays. The precision was within 1 to 15% of RSD. The accuracy was within −5 to 25% of bias. The lower the concentration, the higher the tendency of the bias. Overall the method was accurate enough for screening and diagnostic purposes (Table 1 and Table 2).
Table 1.*RSD=SD/mean×100. Abbreviations: Conc., concentration, SD, standard deviation; RSD, relative standard deviation.
Table 2.*RSD=SD/mean×100. Abbreviations: Conc., concentration, SD, standard deviation; RSD, relative standard deviation.
The matrix effect was evaluated at low (83.3% with 13% CV), medium (89.2% with 8% CV), and high concentrations (91.2 % with 7% CV) (Table 3). The coefficient of variance was less than 15%, showed a slight matrix effect, satisfying the validation criteria. Extraction recovery was in the range of 95-125%, showing reasonable recovery (Table 1 and Table 2).
Table 3.Matrix effect (n=2)
Our developed method was applied to clinical specimens for obtaining Korean normal range of HGA. We measured HGA concentration of normal plasma specimens from healthy volunteers (n=20). Healthy normal men (n=10) and women (n=10) did not show any HGA peak as shown in Fig. 3B and Fig. 3C.
4. Discussion
Without time-consuming solid phase extraction, the new method was validated under a simple sample preparation within a 8.5 min chromatographic separation. The mass spectrum of HGA shows the presence of a TMS derivative with molecular ion [M]+ at m/z 384, the loss of a methyl ion ([M]+-CH3) at m/z 369 from molecular ion, and [M-CH2CH2CH3]+ ion at m/z 341 (Fig. 4).
Formula weight (FW), [M]+ ion, and relative retention time (RRT) versus internal standard were evaluated for selected ion monitoring mode. The quantification ion (QI) was chosen from the ion showing the maximum intensity in the spectra, that did not interfere with ions from other matrix compounds. Generally the [M]+ ion was chosen as confirmation ion (CI). The identification of an HGA was based on the co-elution of selected ion species, the ratio of QI and CI on the GC-MS chromatogram of the plasma specimens. The ratio of peak intensity (QI/CI) is considered as another very important parameter for identification.
REGISIL is the combination of BSTFA and 10% TMCS. TMCS is a catalyst that speeds up the reaction between HGA and BSTFA. Sameeh et al. used 200 µL of BSTFA for derivatization of HGA.10 In the present study, 50 µL REGISIL was sufficient for derivatization because of the catalytic properties of TMCS, which can be considered an advantage of REGISIL over other derivatizing reagents. We used 1% TEA in ACN as a solvent catalyst.
The calibration curve showed excellent linearity with a correlation coefficient of 0.9991. The acceptable precision and accuracy, reasonable matrix effect, and no carryover effects demonstrated the integrity of validation. Determination of the signal-to-noise ratio was performed by comparing the desired signal to the average noise around the signal. The LOD was determined at three times the noise level, and LOQ was determined at 10 times the noise level.
Generally, patients with alkaptonuria show high excretion of abnormal HGA. The HGA concentration in plasma of alkaptonuria patients was previously reported in the range of 33-39 µmol/L,7 and that in urine was 0.46-1.5 g/24 hr.10 The calculated LOD of our method was 0.4 ng/µL (approximately 2.38 µmol/L), which was sensitive enough to detect HGA in plasma of patient with alkaptonuria. LOQ determined in our method was 4 ng/µL (approximately 23.8 µmol/L), which is well below the LOQ reported (30 µmol/L) for LC-MSMS.9 Thus, the proposed LOD and LOQ levels are sensitive enough for both diagnosis and follow-up testing for alkaptonuria patients
The main advantages of this method are the simple liquid-liquid extraction process without an expensive, tedious solid phase extraction step with its great sensitivity and specificity. Secondly, the amount of derivatizing reagent used in this study was only 50 µL, which is very low volume compared to that in other studies.10
5. Conclusions
We developed a simple, fast, and sensitive analytical method for the quantification of HGA in plasma using GC-MS/SIM. This method enabled fast analysis of HGA within 8.5 min with 5 min of derivatization reaction time, which is very much faster compared to previously published analytical approaches.10 Thus, this method could provide a useful analytical and clinical tool for diagnosing monitoring the effect of treatment on HGA level in patients with alkaptonuria.
참고문헌
- H. Z. Paul, S. B. Craig and T. K. Peter, Anal. Chem., 48, 2200-2202 (1976). https://doi.org/10.1021/ac50008a037
- R. A. Milch, Studies of alcaptonuria: inheritance of 47 cases in eighty highly inter-related Dominican kinders. Am. J. Hum. Genet., 12, 76-85 (1960).
- S. Srsen, F. Cisarik, L. Pasztor and L. Harmecko, Alkaptonuria in the Trencin District of Czechoslovakia, Am. J. Med Genet., 2, 159-166 (1978). https://doi.org/10.1002/ajmg.1320020207
- M. A. Essa, L. A. Shamsan, M. S. Rashed and P. T. Ozand, Ann. Saudi Med., 18, 442-444 (1998). https://doi.org/10.5144/0256-4947.1998.442
- C. Phornphutkul, W. J. Introne, M. B. Perry, I. Bernardini, M. D. Murphey and D. L. Fitzpatrick. N. Engl. J. Med., 347, 2111-2121 (2002). https://doi.org/10.1056/NEJMoa021736
- J. E. Seegmiller, V. G. Zannoni, L. Laster and B. N. La Du, J. Biol. Chem., 236, 774-777 (1961).
- C. Bory, R. Boulieu, C. Chantin and M. Mathieu, Clin Chem., 35, 321-322 (1989).
- A. P. Markus, D. W. Swinkels, B. S. Jakobs, R. A. Wevers, J. M. Trijbels and H. L. Willems. Anal. Chim. Acta, 429, 287-292 (2001). https://doi.org/10.1016/S0003-2670(00)01286-1
- A. T. Hughes, A. M. Milan, P. Christensen, G. Ross, A. S. Davison, J. A. Gallagher, J. J. Dutton and L. R. Ranganath, J. Chromatogr. B., 963, 106-112 (2014). https://doi.org/10.1016/j.jchromb.2014.06.002
- A. S. Sameeh, N. T. Ibrahim, S. S. Mohammed, M. A. Eman, M. S. Jehad and M. S. Yousef, Jordan J. Biol. Sci., 7, 195-198 (2014). https://doi.org/10.12816/0008238
- R. K. Daniel, Introduction. In: Daniel RK, ed. Handbook of analytical derivatization reactions. New York: John Wiley and Sons., 9-10 (1979).
- C. D. John, R. Cheruppolil and S. Kumar, J. Chromatogr. B., 667, 147-151(1995).
- Food and drug administration http://www.fda.gov/downloads/Drugs/Guidances/ ucm070107.pdf
- R. Causon. J. Chromatogr. B., 689, 175-180 (1997). https://doi.org/10.1016/S0378-4347(96)00297-6